Figure 2.

Pharmacokinetics, expressed as a percentage of the injected dose (%ID) in blood, of (A) ⁶⁴Cu-DOTA, ⁶⁴Cu-DOTA-PEG, and ⁶⁴Cu-NS at 5 minutes, and at hours 1, 4, 20, and 42 after intratumoral injection, and (B) ⁶⁴Cu-nanoshells administered by intratumoral versus intravenous injection.

Notes: The data points are the average values of three rats for ⁶⁴Cu-DOTA and ⁶⁴Cu-DOTA-PEG and the average values of four animals for ⁶⁴Cu-nanoshells (average ± standard deviation). The curves are the simulated three-parameter single exponential decay. Significant difference between intratumoral and intravenous administration of ⁶⁴Cu-nanoshells is evident at hours 1, 4, 20, and 42 after injection (P <0.05).

Abbreviations: PEG, polyethylene glycol; DOTA, 1,4,7,10-tetraazaciclododecane-1,4,7,10-tetraacetic acid; NS, gold nanoshells; IT, intratumoral; IV, intravenous.